Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 35INDUSTRY 33NIH 6OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 1

Interventions

Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Cyclophosphamide 3Busulfan 3Whole-Body Irradiation 2Mycophenolic Acid 2Cytarabine 2Cyclosporine 2ruxolitinib 1merphos 1liposomal amphotericin B 1hydrocortisone hemisuccinate 1fludarabine phosphate 1fludarabine 1Watchful Waiting 1Thioguanine 1Tacrolimus 1Stem Cell Transplantation 1Psychiatric Rehabilitation 1Photopheresis 1Pentostatin 1Patient Reported Outcome Measures 1Moxifloxacin 1Morphine 1Methoxsalen 1Mesna 1Melphalan 1In Situ Hybridization, Fluorescence 1Idarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Myelomonocytic, Chronic × Azacitidine × Clear all
NCT01048034 2013-10-29

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Nordic MDS Group

Phase 2 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡